TWI884914B - 喋啶酮化合物及其用途 - Google Patents
喋啶酮化合物及其用途 Download PDFInfo
- Publication number
- TWI884914B TWI884914B TW108114117A TW108114117A TWI884914B TW I884914 B TWI884914 B TW I884914B TW 108114117 A TW108114117 A TW 108114117A TW 108114117 A TW108114117 A TW 108114117A TW I884914 B TWI884914 B TW I884914B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- cancer
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661744P | 2018-04-24 | 2018-04-24 | |
| US62/661,744 | 2018-04-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202010744A TW202010744A (zh) | 2020-03-16 |
| TWI884914B true TWI884914B (zh) | 2025-06-01 |
Family
ID=66655428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108114117A TWI884914B (zh) | 2018-04-24 | 2019-04-23 | 喋啶酮化合物及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11059826B2 (enExample) |
| EP (1) | EP3784669B1 (enExample) |
| JP (2) | JP7479293B2 (enExample) |
| CN (1) | CN112218865B (enExample) |
| AR (1) | AR114828A1 (enExample) |
| AU (1) | AU2019257651B2 (enExample) |
| CA (1) | CA3097774A1 (enExample) |
| ES (1) | ES2969982T3 (enExample) |
| IL (1) | IL278122B2 (enExample) |
| TW (1) | TWI884914B (enExample) |
| WO (1) | WO2019209757A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| AU2020214258B2 (en) * | 2019-01-29 | 2025-08-28 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| US20230322767A1 (en) | 2020-07-29 | 2023-10-12 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| CN117088878A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| TW202333697A (zh) * | 2022-01-30 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Ｗｎｔ通路抑制劑化合物 |
| CN114436918B (zh) * | 2022-02-23 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在药物中的应用 |
| CN117396482B (zh) * | 2022-07-28 | 2026-02-27 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006018182A1 (en) * | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060052383A1 (en) * | 2004-08-25 | 2006-03-09 | Boehringer Ingelheim International Gmbh | New dihydropteridione derivatives, process for their manufacture and their use as medicament |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| UA76512C2 (en) | 2001-09-04 | 2006-08-15 | Boehringer Ingelheim Pharma | Dihydropteridinones, a method for producing thereof and use thereof as medicament |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| AU2011226830A1 (en) * | 2004-08-14 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CA2617589A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US8865716B2 (en) * | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| JP6052527B2 (ja) | 2013-02-21 | 2016-12-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンｉ |
| WO2014127816A1 (en) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydropteridinones ii |
| MX2016009975A (es) * | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
| WO2015193229A1 (de) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| WO2016201370A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN105801582A (zh) | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
| ES2969982T3 (es) * | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
-
2019
- 2019-04-23 ES ES19726791T patent/ES2969982T3/es active Active
- 2019-04-23 EP EP19726791.7A patent/EP3784669B1/en active Active
- 2019-04-23 WO PCT/US2019/028604 patent/WO2019209757A1/en not_active Ceased
- 2019-04-23 AU AU2019257651A patent/AU2019257651B2/en active Active
- 2019-04-23 CA CA3097774A patent/CA3097774A1/en active Pending
- 2019-04-23 IL IL278122A patent/IL278122B2/en unknown
- 2019-04-23 TW TW108114117A patent/TWI884914B/zh active
- 2019-04-23 CN CN201980035546.1A patent/CN112218865B/zh active Active
- 2019-04-23 AR ARP190101061A patent/AR114828A1/es unknown
- 2019-04-23 JP JP2020559365A patent/JP7479293B2/ja active Active
- 2019-04-23 US US16/391,407 patent/US11059826B2/en active Active
-
2021
- 2021-03-01 US US17/188,132 patent/US11572364B2/en active Active
-
2022
- 2022-12-05 US US18/075,270 patent/US12384790B2/en active Active
-
2023
- 2023-06-15 JP JP2023098522A patent/JP2023116712A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006018182A1 (en) * | 2004-08-14 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060052383A1 (en) * | 2004-08-25 | 2006-03-09 | Boehringer Ingelheim International Gmbh | New dihydropteridione derivatives, process for their manufacture and their use as medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2969982T3 (es) | 2024-05-23 |
| JP2021522237A (ja) | 2021-08-30 |
| EP3784669A1 (en) | 2021-03-03 |
| US20220363685A1 (en) | 2022-11-17 |
| IL278122B1 (en) | 2023-09-01 |
| US12384790B2 (en) | 2025-08-12 |
| EP3784669B1 (en) | 2023-10-25 |
| US20230312587A1 (en) | 2023-10-05 |
| WO2019209757A1 (en) | 2019-10-31 |
| JP7479293B2 (ja) | 2024-05-08 |
| JP2023116712A (ja) | 2023-08-22 |
| US11059826B2 (en) | 2021-07-13 |
| AU2019257651B2 (en) | 2023-05-25 |
| TW202010744A (zh) | 2020-03-16 |
| CN112218865A (zh) | 2021-01-12 |
| CN112218865B (zh) | 2024-03-12 |
| US11572364B2 (en) | 2023-02-07 |
| IL278122A (en) | 2020-11-30 |
| AR114828A1 (es) | 2020-10-21 |
| AU2019257651A1 (en) | 2020-10-15 |
| IL278122B2 (en) | 2024-01-01 |
| US20190322673A1 (en) | 2019-10-24 |
| CA3097774A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI884914B (zh) | 喋啶酮化合物及其用途 | |
| CN116554168B (zh) | Cxcr4抑制剂及其用途 | |
| AU2020282759A1 (en) | TEAD inhibitors and uses thereof | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| KR20230172548A (ko) | Mek 억제제 및 이의 용도 | |
| WO2022120355A1 (en) | Tead degraders and uses thereof | |
| JP2019518768A (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
| TW202146393A (zh) | Eif4e抑制劑及其用途 | |
| CA3098335A1 (en) | Antiproliferation compounds and uses thereof | |
| JP2025523621A (ja) | Ｕｓｐ１阻害剤及びその使用 | |
| JP2022538138A (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| HK40050670A (en) | Substituted piperidines as cxcr4-inhibitors | |
| EA047483B1 (ru) | Ингибиторы tead и их применения | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof |